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Abstract  
Serotonin is probably best known for its role in conveying a sense of contentedness and 
happiness. It is one of the most unique and pharmacologically complex monoamines in 
both the peripheral and central nervous system (CNS). Serotonin has become in focus of 
interest for the treatment of depression with multiple serotonin-mimetic and modulators of 
adult neurogenesis used clinically. Here we will take a broad view of serotonin from 
development to its physiological role as a neurotransmitter and its contribution to 
homeostasis of the adult rodent hippocampus. This chapter reflects the most significant 
findings on cellular and molecular mechanisms from neuroscientists in the field over the 
last two decades. We illustrate the action of serotonin by highlighting basic receptor 
targeting studies, and how receptors impact brain function. We give an overview of recent 
genetically modified mouse models that differ in serotonin availability and focus on the role 
of the monoamine in antidepressant response. We conclude with a synthesis of the most 
recent data surrounding the role of serotonin in activity and hippocampal neurogenesis. 
This synopsis sheds light on the mechanisms and potential therapeutic model by which 
serotonin plays a critical role in the maintenance of mood.  
 
Introduction 
Our knowledge of the biology of serotonin (5-hydroxytryptamine, 5-HT) and its function in 
the peripheral and CNS has been rapidly growing. This is likely due to the cloning of the 
multiple receptor subtypes that mediate serotonin signaling and the advent of new 
technologies to selectively perform gain- or loss-of-function studies. In this review we focus 
on serotonin activity in the rodent brain, and particularly concentrate on the role of 
serotonin in adult hippocampal neurogenesis. The discovery of newly generated neurons 
throughout life (Altman and Das, 1965, Kaplan and Hinds, 1977) has not only altered the 
perception of the general public that the brain lacks the capacity for neuron replacement 
but also opens novel fields of neuroscience research. Serotonin contributes to this 
fascination as one of the crucial signals in the neurogenic niche microenvironment 
together with other growth factors, hormones, or neurotransmitters that regulate cell 
proliferation and differentiation.  
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Neurogenic niches are only a few spatially restricted regions consisting of neural 
stem cells that retain fate plasticity and can respond to environmental stimuli 
(Kempermann et al., 1997, van Praag et al., 1999, Doetsch and Hen, 2005). These are the 
subventricular zone (SVZ), where new neurons contribute to encoding olfactory 
information, and the subgranular zone (SGZ) of the dentate gyrus (DG). In the adult DG, 
neurogenesis comprises six developmental steps, where radial glia-like stem cells (type-1, 
1st) give rise to proliferating amplified progenitor cells (type-2a/b and type-3, 2nd to 4th) that 
become immature (5th) and mature (6th) neurons (Kempermann et al., 2004, Hodge et al., 
2008) (Figure 1A). The common method to examine neurogenesis includes proliferation 
and differentiation of precursor cells that can be detected by incorporation of the thymidine 
analog bromodeoxyuridine (BrdU), and specific marker expression such as Sox2 (type-1 
and type-2) or DCX (doublecortin) that characterizes transiently amplified progenitor cells 
of the neuronal lineage (type-2b/3). While proliferation is determined two to 24 hours after, 
survival of newborn neurons is analyzed several times post-injection of BrdU; the time 
newborn cells get structurally and functionally integrated into the network is within three to 
seven weeks (Lie et al., 2004). The young adult rat DG generates approximately 9,000 
cells/day (6% of the total granule cell population per month) that drastically declines with 
aging (Kuhn et al., 1996, Cameron and McKay, 2001). 
Serotonin plays a role in many homeostatic systems as evidenced by the results 
showing that deregulation of the serotonin system leads to neurogenic decline, changes in 
appetite, and mood disorders. Whether neurogenic decline is causative or associative with 
these pathologies remains to be determined. In the case of depression, chronic 
manipulation of serotonin by agents that inhibit serotonin reuptake, leads to clinical 
improvement associated with a slow, temporal increase in adult hippocampal 
neurogenesis (Malberg et al., 2000, Santarelli et al., 2003). While the mechanism of 
serotonin action in the hippocampus is just being illuminated, there is considerably less 
known regarding its function in SVZ neurogenesis (Banasr et al., 2004, Ohira and 
Miyakawa, 2011).  
The first part of this chapter will summarize studies on robust pharmacological 
depletion or enhancement of serotonin levels that affect granule cells in the DG. We will 
discuss the modulator role of several 5-HT receptors and their contribution to homeostasis 
of adult neurogenesis. As we will see, serotonin exerts a pro-neurogenic effect that is 
mediated through a complex network of receptors, many of which remain to be tested. We 
focus on the receptors addressed the most: 5-HT1A, 5-HT2A and 2C, and summarize the 
key findings. The review will continue with a variety of recently generated animal models 
that provide controlled regulation of serotonin supply and have been used to characterize 
alterations in baseline proliferation and survival of newborn cells. It is important to define 
serotonin’s essential roles in brain function and behavior, as it is equally important to 
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discover the regulators and interactive pathways by which serotonin mediates brain 
function. In this regard, we have recently tested serotonin action in a loss-of-function 
model in which the availability of brain-derived serotonin is selectively depleted (Alenina et 
al., 2009, Klempin et al., 2013). These data together with others from genetically modified 
mouse models shed a distinct light on the mechanisms proposed in earlier studies to be 
reviewed here. We will also consider the anticipated role of serotonin in the antidepressant 
response and increased neurogenesis and thus address and review the 
monoamine/neurotrophin hypothesis. Finally we will point toward new directions for future 
research and discuss the promise of uncovering mechanisms where serotonin may be 
manipulated to affect memory and mood disorders. 
 
The effect of pharmacological serotonin depletion or enhancement on baseline 
neurogenesis  
Serotonin is synthesized in neurons of the brain stem raphe nuclei (reviewed in (Gaspar et 
al., 2003)) from the amino acid tryptophan by a short metabolic pathway, consisting of the 
neuron-specific enzyme tryptophan hydroxylase (TPH) 2 (Walther et al., 2003). Once 
serotonin is synthesized it is packed into synaptic vesicles by the vesicular monoamine 
transporter (VMAT) 2. Extracellular levels of serotonin are regulated by its re-uptake into 
the presynaptic cell through its specific (serotonin) transporter (SERT). The transcription 
factors Lmx1b and Pet1 are expressed in serotonergic neurons in the raphe nuclei during 
development. Pet1 directly controls the expression of the genes encoding TPH2, 5-HT1A 
receptor, and SERT (Liu et al., 2010) by binding a conserved cis-regulatory element in 
these genes (Hendricks et al., 1999). 
Serotonergic fibers project throughout the brain and into the DG of the hippocampus 
where they synapse with granule cells and interneurons. Here, serotonin is an important 
intrinsic soluble factor that promotes neuronal development (Brezun and Daszuta, 2000, 
Radley and Jacobs, 2002, Santarelli et al., 2003, Banasr et al., 2004); but data on whether 
this stimulation primarily affects cell proliferation or survival of newly generated neurons 
are contradictory. First evidence of serotonin’s modulator role in the adult DG originates 
from pharmacological manipulation studies based on lesion of serotonergic neurons in the 
raphe (by injection of 5,7-Dihydroxytryptamine, DHT) (Brezun and Daszuta, 2000, Jha et 
al., 2006) or inhibition of serotonin synthesis (by para-chlorophenylalanine, PCPA) (Huang 
and Herbert, 2005b, Jha et al., 2006). While the first method robustly destroys fibers and 
possibly cells, PCPA treatment inhibits the synthesizing enzyme TPH. Yet, both methods 
have been shown to decrease hippocampal serotonin levels and adult neurogenesis 
(Brezun and Daszuta, 2000, Jha et al., 2006). In turn, raphe grafts can restore 
serotonergic control and the number of proliferating precursor cells and immature neurons 
in the DG (Brezun and Daszuta, 2000). Serotonin depletion also leads to a decrease in 
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dendritic spine density of granule cells (Yan et al., 1997). However, controversial data exist 
showing that PCPA treatment, but not the neurotoxin 5,7-DHT (Huang and Herbert, 
2005b) might decrease the number of precursor cells at 1 day and 4 weeks later (Jha et 
al., 2006), while chronic PCPA treatment also leads to increased survival of precursor cells 
in the DG of wild type animals mimicking models with serotonin deficiency (Diaz et al., 
2013). On balance, data from these studies reveal that serotonin depletion or a decline in 
serotonin synthesis has long-term regulatory effects on adult hippocampal neurogenesis, 
however with noticeable contradictive effects.  
Further evidence of serotonin’s modulator role on generating new neurons in the adult 
brain has been achieved by studies on selective serotonin reuptake inhibitors (SSRIs) 
(Malberg and Duman, 2003, Santarelli et al., 2003, Encinas et al., 2006, Wang et al., 2008, 
Klempin et al., 2010). SSRIs mode of action is an immediate increase in the synaptic 
availability of serotonin with the acute administration facilitating serotonergic transmission 
and transient desensitization of 5-HT1A autoreceptors. Chronic treatment of this class of 
antidepressants induces re-establishment of the serotonin system by long-term 
downregulation of SERT and 5-HT1A autoreceptor activities (Blier and Ward, 2003, 
Descarries and Riad, 2012). Chronic, but not acute, treatment with fluoxetine (trade name 
‘Prozac’) also leads to increased hippocampal neurogenesis, e.g. increased cell 
proliferation and number of newborn neurons (Malberg et al., 2000, Santarelli et al., 2003, 
Encinas et al., 2006, Klempin et al., 2010). Later we will review the characteristic delay 
observed in serotonin-based drug efficiency, and return to the mechanism underlying the 
antidepressant hypotheses from animal studies and a clinical perspective.  
 
Pharmacological 5-HT receptor targeting studies and baseline neurogenesis 
Serotonin’s role in the hippocampus has been extensively discussed relying on studies 
using pharmacological depletion or receptor targeting. We have recently shown that 5-HT1 
and 2 receptor subtypes control both acute and chronic effects of serotonin release that 
modulate different developmental steps in adult neurogenesis (Klempin et al., 2010). 
Serotonergic targets within the DG express a variety of 5-HT receptors that in turn dictate 
the response from efferent activity (Brezun and Daszuta, 2000, Klempin et al., 2010, Diaz 
et al., 2013). Their expression pattern varies with 5-HT1A receptor immunoreactivity found 
on type-1 to type-2b cells in the SGZ as well as on interneurons. For 5-HT2A receptors, 
labeling revealed a dense staining in the hilus, whereas 5-HT2B (Diaz et al., 2013) and 5-
HT2C receptors mostly mark adult granule cells (Klempin et al., 2010). 5-HT3 receptor 
mRNA expression was seen in hilar interneurons (Tecott et al., 1993) that was confirmed 
by in situ hybridization (Diaz et al., 2013). We hypothesize that the distinct actions of 
receptor subtypes could mediate the homeostasis of serotonin signaling in the 
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hippocampus. In the following, we are reviewing studies on receptor targeting by 
manipulation with a variety of agonist and antagonists. 
A predominant mediator of serotonin action is the 5-HT1A receptor subtype as seen in 
neurosphere cultures and selective receptor targeting studies in rat and mouse models. 
Neurosphere assays are used to investigate neural stem cells in vitro and to define their 
stemness and multipotency. Under proliferation conditions, neural stem cells produce both, 
TPH and serotonin, and express 5-HT1A receptors (Benninghoff et al., 2010, Klempin et 
al., 2010). Self-renewal and proliferation is decreased by 5-HT1A blockage or PCPA 
treatment that is rescued by exogenous serotonin. Acute targeting of 5-HT1A postsynaptic 
receptors with selective antagonists in vivo has been shown to reduce the number of 
newly generated cells in the DG (Radley and Jacobs, 2002) whereas acute stimulation had 
the opposite effect (Banasr et al., 2004, Klempin et al., 2010). Furthermore, chronic 
activation also increases proliferation, while prolonged inhibition of 5-HT1A receptors 
results in a decrease in net neurogenesis (Banasr et al., 2004, Klempin et al., 2010). 
Combined treatment with PCPA (or following 5,7-DHT, respectively) and activation of 5-
HT1A postsynaptic receptors increases precursor cell proliferation in the DG (Huang and 
Herbert, 2005a). Activating 5-HT1B receptor subtypes also seem to mediate the 
proliferative effect as recovery was observed following PCPA treatment in rats (Banasr et 
al., 2004). The decrease in dendritic length and loss of spine density observed after 
serotonin depletion is due to decreased 5-HT1A receptor activation as the same effects 
have been seen following 5-HT1A antagonist treatment (Yan et al., 1997). The effect was 
reversed by stimulation with a selective 5-HT1A agonist. Overall synaptogenesis seems to 
be mediated by 5-HT1A receptor signaling (Mogha et al., 2012). Interestingly, 
pharmacological manipulation of the 5-HT2 receptor family reveals distinctive results not 
only to 5-HT1A receptor targeting but also between studies. Acute activation of the 5-
HT2C receptor subtype has been shown to decrease cell proliferation resembling the 
effects of 5-HT1A antagonist or has no effect (Banasr et al., 2004, Klempin et al., 2010). 
Vice versa, acute blocking produces more BrdU-labeled cells lacking antagonistic action. 
We proposed that acute activation of one receptor subtype (5-HT1A) stimulates the 
production of cells that is lost after prolonged stimulation; yet, the increase in cell numbers 
is affected by another receptor subtype (5-HT2C) that stimulates both the number of 
proliferating late-stage precursor cells and net adult neurogenesis (Klempin et al., 2010). 
Neurosphere cultures also demonstrate the differential contribution of 5-HT1A and 5-HT2 
receptors in both self-renewal of precursor cells, and promoting neuronal differentiation 
(Klempin et al., 2010). Nevertheless, results on receptor targeting seem to depend on the 
experimental design and the drugs used, in addition to possible interaction of 
glutamatergic and serotonergic signaling (McEwen et al., 2010).  
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Together with SERT 5-HT receptors are also targets for pharmacotherapy: In 
depression, SSRIs are thought to primarily inhibit serotonin reuptake into the presynaptic 
cell and to target 5-HT1A auto-receptors (Descarries and Riad, 2012); 5-HT2 receptors 
can be targets in obesity and following stroke as increased 5-HT2 receptor density seems 
to correlate with attenuation of symptoms of depressed mood that goes along with these 
diseases (Nigro et al., 2013). It has been further shown that in the absence of functional 5-
HT2B receptors extracellular serotonin levels are reduced while treatment with selective 5-
HT2B agonists induces an antidepressant-like response (Diaz et al., 2012). Studies also 
described the impact of the 5-HT2C receptor subtype that mimics the effect of 
antidepressant action by increasing precursor cell proliferation and survival (Soumier et al., 
2009, Klempin et al., 2010). Recently, a study also proposed 5-HT4 receptor-mediated 
signaling in antidepressant action that reverses de-maturation of adult granule cells as this 
developed together with enhanced efficacy of serotonin-neuromodulation via 5-HT4 
receptors (Kobayashi et al., 2010, Mendez-David et al., 2014). As we have seen, 
differential receptor targeting on sequential steps in the course of adult neurogenesis 
modulates proliferation and survival of hippocampal precursor cells (Figure 1B) (Brezun 
and Daszuta, 2000, Encinas et al., 2006, Klempin et al., 2010). However, the 
heterogeneity and varied localization of 5-HT receptor subtypes within the hippocampal 
niche has made it challenging to understand the site and mechanism of action of 
pharmacotherapy. Importantly, receptor activation is dynamic both temporally and 
spatially, and for future work on the receptors reviewed here and others it is likely to be 
necessary to develop a model of the signaling network created by the many receptor 
species. 
 
Animal models: addressing the controversy of serotonin’s role in proliferation or survival of 
newly generated cells  
Serotonin functions in the CNS have been studied extensively by pharmacological 
approaches. Nowadays, new technologies give the advantage of generating animal 
models that allow selective manipulation of the serotonin system by gain- or loss-of-
function studies in the brain. Genetic animal models have been developed that target 
serotonin receptor subtypes (5-HT1A), genes that are involved in serotonin synthesis 
(TPH2), vesicular packaging (VMAT2), or serotonin re-uptake (SERT). However, our 
knowledge regarding the role and effects on adult hippocampal neurogenesis in these 
models is still limited.  
First approaches focused on the 5-HT1A KO mouse model due to its proposed 
predominant role in serotonin’s influence on neurogenesis based on receptor targeting 
studies as described above. Despite the large number and variability of receptors in the 
DG, one receptor subtype seems to be sufficient to produce the effect on homeostasis 
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within the neurogenic niche (Santarelli et al., 2003). Although in this study, no differences 
in cell proliferation were observed in 5-HT1A KO animals compared to wild type, treatment 
with the selective 5-HT1A receptor agonist 8-OH DPAT confirmed its modulatory role, as 
no stimulation of proliferation in 5-HT1A KO mice was seen (Santarelli et al., 2003).  
The advantage of other mouse models that are developmentally depleted in serotonin 
supply has been recently discovered. Elucidation of adult hippocampal neurogenesis 
revealed no measurable changes in baseline proliferation of precursor cells in mice that 
are almost devoid of brain serotonin (Tph2-/-, VMAT2SERT-Cre) or with a drastic reduction in 
serotonin levels (Tph2KI, Pet1-/-) (Diaz et al., 2013, Klempin et al., 2013, Sachs et al., 
2013). Considering the results reviewed above on pharmacological depletion of serotonin 
signaling that leads to a decrease in neurogenesis, it is surprising that sustained 
neurogenesis can occur in the absence of serotonin. This is most probably a result of 
developmental compensation evoked by its life-long depletion/reduction. The mechanism 
of compensation could have significant clinical relevance for restoring serotonin 
homeostasis in models of disease. For Tph2-/- mice, although no change in overall 
proliferation was detected, there is a deficiency in the transition from type-1 stem cells to 
type-2 progenitors with an altered balance of precursor cell proliferation and cell death 
rate, accompanied by changes in the number of Sox2-expressing cells (Klempin et al., 
2013). We suggested population changes on the cellular level in the absence of serotonin 
as potential compensatory mechanism that maintains the progenitor cell pool and thus 
homeostasis in Tph2-/- mice. Whether compensation is also due to adaptations at the level 
of 5-HT receptors and their downstream pathways, or alterations in neurotrophic factor 
signaling such as an increase in hippocampal brain-derived neurotrophic factor (BDNF) 
expression (Migliarini et al., 2012, Sachs et al., 2013) induced by developmental deficiency 
in brain serotonin needs to be determined. In the model of congenital serotonin deficiency 
(Tph2KI), increased numbers of DCX-expressing cells have been found showing a shift 
towards late-stage progenitor cells (Sachs et al., 2013).  
Surprisingly, too, evaluations of the survival and differentiation of newly generated neurons 
show a positive effect by increased cell numbers in models of decreased serotonergic 
transmission, e.g., Tph2KI, Pet1-/-, VMAT2SERT-Cre (Diaz et al., 2013, Sachs et al., 2013) 
that is normalized by chronic treatment with 8-OH DPAT in Pet1-/- mice (Diaz et al., 2013). 
Increased survival in these models that was also seen following chronic serotonin 
inhibition by PCPA in one study (Diaz et al., 2013) argues for a compensatory effect in 
these mice where loss of newborn neurons normally balances neurogenesis (Biebl et al., 
2000). However, mouse models with life-long depletion in central serotonin exhibit effects 
that differ from data and knowledge gained by pharmacological manipulation studies. A 
thorough examination of altered modulation of adult neurogenesis in mice with constitutive 
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versus inducible serotonin deficiency is necessary to differentiate between acute and life-
long effects of low serotonin availability.  
Serotonin depletion in transgenic mouse models also results in altered behavior such as 
exaggerated aggressiveness that goes along with reduced anxiety (Mosienko et al., 2012) 
and increased impulsivity (Angoa-Perez et al., 2012). Increased escape-like reactions 
have been observed in the tail suspension test in VMAT2SERT-Cre (Narboux-Neme et al., 
2011) but not Tph2-/- mice (Mosienko et al., 2012) revealing conflicting results. 
Nevertheless, brain serotonin-deficient mice do not exhibit the expected ‘depression 
model’ phenotype (reviewed in (Fernandez and Gaspar, 2012, Mosienko et al., 2014); that 
may reflect unchanged baseline neurogenesis, but also indicates an uncoupling of the 
behavioral mechanisms governing depression and serotonin levels in a unique 
homeostasis created over time. Compensatory mechanisms seem to occur in life-long 
serotonin depletion and the replacement of this neurotransmitter by expression or activity 
of other neurotransmitter systems has been debated (Beckman and Santos, 2013). In 
Tph2-/- mice, the hippocampus reveals a reduction in norepinephrine (NE) or dopamine 
(DA) levels (Gutknecht et al., 2012) that could partly mediate an effect on adult 
neurogenesis. However, data reviewed here show no changes in cell proliferation in 
serotonin-deficient mouse models at baseline arguing that reduced NE or DA 
concentrations in these animals do not affect homeostasis of neurogenesis.  
Noticeable, serotonergic neurons and fibers persist in the adult brain of serotonin-
depleted mice (Gutknecht et al., 2008, Alenina et al., 2009, Migliarini et al., 2012) raising 
the question of their functional role when serotonin is absent. The neuromodulator 
character of serotonin affects excitatory or inhibitory release mediated by glutamate or 
GABA (Schmitz et al., 1995, Li et al., 2000) with one study showing that serotonergic 
neurons itself can express the GABA-synthesizing enzyme glutamic acid decarboxylase 
(Fu et al., 2010). Furthermore, two-thirds of dorsal raphe Pet1 neurons exhibit vesicular 
glutamate transporter 3 that is required for glutamate release (Hioki et al., 2010, Liu et al., 
2014). In a recent study, these neurons revealed rapid changes in neuronal activity during 
a reward test by releasing both serotonin and glutamate (Liu et al., 2014). When serotonin 
is absent, nerve fibers may retain a default phenotype, where co-transmitters continue to 
be regulated normally. Yet, data on the non-/existence of co-transmission of serotonin and 
neuropeptides such as somatostatin, galanin or substance P in the dorsal raphe are 
obscure and vary between species with a tendency to ‘no evidence’ as shown in a recent 
study (Fu et al., 2010).  
Another genetically modified mouse model that is deficient in SERT (5-HTT–/–) 
exhibits increased extracellular serotonin levels, and reveals increased cell proliferation in 
aged but not adult mice (Schmitt et al., 2007). Like-wise, an age-dependent increase in the 
anxiety-like behavior was observed associated with changes in spine density in the 
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prefrontal cortex and amygdala (Sakakibara et al., 2014). These results argue for another, 
undetermined chronic compensatory pathway induced by changes in serotonin levels. 
Although survival and differentiation of newborn neurons were not affected, increased 
numbers of proliferating cells have been observed in the CA3 region of mouse 
hippocampus (Karabeg et al., 2013), whereas adult rat deficient in SERT showed 
increased numbers of immature neurons expressing DCX in the DG (Schipper et al., 
2011). SERT knockdown by siRNA in adulthood also contributes to antidepressant action 
(Ferres-Coy et al., 2013). However, data gained from this mouse model are few and 
further research is necessary to better define its phenotype.  
 
Neurogenesis/monoamine/neurotrophin hypothesis of antidepressant action  
Most studies on serotonin function in the brain focus on its correlation with neurogenesis 
and clinical disorders. The “neurogenesis or monoamine hypothesis” of depression is 
supported by the observation that most commonly used antidepressant drugs target the 
serotonin system and facilitate adult hippocampal neurogenesis (reviewed in 
(Kempermann and Kronenberg, 2003, Warner-Schmidt and Duman, 2006, Czeh and 
Lucassen, 2007, Sahay and Hen, 2007). In turn, a decline in neurogenesis accompanied 
by low levels of critical neurogenic modulators is associated with mood disorders. 
Depression has become a common disease in industrialized countries affecting a growing 
number of its population. Major depression can also develop following dementia or stroke 
and goes along with anxiety, alcohol dependence, and other psychiatric disorders. In the 
clinics modern antidepressants are used efficiently with the immediate action to alter the 
synaptic availability of the monoamine serotonin. However, today’s serotonin 
pharmacotherapy is based on treatment outcome that lacks a clear understanding of the 
underlying therapeutic mechanisms but also the pathways that produce counter-
indications, and research into the mechanisms of antidepressant action has been 
challenging.  
As described above SSRIs are thought to target the serotonin system by inhibiting SERT 
function and rely on possible long-term adaptations of 5-HT pre-, and post-synaptic 
receptor subtypes. 5-HT1A, 5-HT2B, 2C and 5-HT4 receptors are soaring candidates for 
contribution to the antidepressant response, as they regulate normal development of 
dendritic spine density and synapse formation of pyramidal and granule cells in the DG, 
elicit long-term plastic changes that decrease anxiety-like behavior, and mediate normal 
maturation of late-stage progenitor cells (Yan et al., 1997, Santarelli et al., 2003, Banasr et 
al., 2004, Klempin et al., 2010, Kobayashi et al., 2010, Diaz et al., 2012, Mendez-David et 
al., 2014). In human studies, increased angiogenesis correlates with increased numbers of 
neural precursor cells in the DG following SSRI or tricyclic antidepressant (TCA) treatment 
(Boldrini et al., 2012).  
	   10	  
Prolonged treatment with the commonly used drug fluoxetine (Flx) has been shown to 
increase survival of newly generated neurons in the DG, whereas short-term treatment 
had no effect (Malberg et al., 2000). Depending on the design, BrdU injections given 
before and after chronic treatment with Flx show increased precursor cell proliferation and 
number of newborn neurons as result of the antidepressant treatment (Malberg et al., 
2000, Santarelli et al., 2003, Encinas et al., 2006, Klempin et al., 2010), whereas survival 
of BrdU-positive cells is only detected 28 days post-injection of BrdU that followed long-
term treatment with Flx (Malberg et al., 2000). Chronic treatment also accelerates 
synaptogenesis and increased LTP and behavior in the hippocampal neurogenic niche 
(Wang et al., 2008). It might also affect overall relative composition of the precursor cell 
pool that led to symmetric divisions of an early progenitor cell class (Encinas et al., 2006). 
The delay in neurogenic response is a potential mechanism to explain the latency in the 
clinical effect of antidepressants (Klempin et al., 2010), and we have indicated this to be a 
balanced interplay of 5-HT1A and 5-HT2C receptor subtypes (as described in the 
paragraph above). Other recent studies reveal Flx’s additional effect on DA receptors, and 
levels of neurotrophic signaling (Kobayashi et al., 2012, Lesemann et al., 2012). In 
accordance to the delayed effects of antidepressant action, a crucial involvement of cyclic 
AMP regulatory element-binding protein (CREB) (Palmer et al., 1997, Chen et al., 2001) 
and non-monoamine-based antidepressants have been suggested (Berton and Nestler, 
2006).  
Recently, the role of neurotrophins in the pathology of depression has been discussed with 
BDNF as critical modulator. Both signaling systems, serotonin and BDNF, are involved in 
the regulation of neural circuitries and antidepressant action, and also co-regulate each 
other (Mattson et al., 2004, Ferres-Coy et al., 2013). A decline in BDNF signaling goes 
along with neurodegeneration and behavioral changes related to chronic stress, whereas 
re-establishing BDNF levels may be the cause of therapeutic responses to 
antidepressants (Duman et al., 1997). Acute treatment with the 5-HT2A/C agonist DOI has 
been shown to decrease BDNF mRNA levels in the granule cell layer of the DG, while 
chronic administration results in desensitization of BDNF signaling (Vaidya et al., 1997). A 
novel antidepressant drug, agomelatine increases the survival of cells via melatonergic 
receptor agonistic, and 5-HT2C receptor antagonistic action that is further accompanied by 
increased BNDF signaling (Soumier et al., 2009). Furthermore, increased serum BDNF 
levels have been found during SSRI treatment in patients (Molendijk et al., 2011). BDNF 
signaling may also contribute to the latency effect since acute injection of BDNF into the 
hippocampus seems to counteract early effects of the SSRI by increasing SERT function 
(Benmansour et al., 2008). The delay is reduced by acute knockdown of SERT that leads 
to enhanced serotonin release accompanied by increased neurotrophic signaling and 
neurogenesis (Ferres-Coy et al., 2013). Further, therapeutic activity of antidepressant 
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drugs might result from an increase in BDNF synthesis in astrocytes (Quesseveur et al., 
2013).  
However, the effects of BDNF on adult hippocampal neurogenesis remain controversial 
(Deltheil et al., 2008). We have recently shown, that brain serotonin deficiency has no 
effect on baseline neurogenesis that may be compensated by altered neurotrophic/BDNF 
signaling. We have proposed BDNF as candidate for permanent compensation in 
serotonin deficient mice and recent data already reveal enhanced BDNF mRNA levels in 
Tph2-/- and Tph2KI mice (Migliarini et al., 2012, Sachs et al., 2013), although accompanied 
by increased serotonin fiber density in the hilus. Nevertheless, whether BDNF signaling is 
related to the clinical features of depression and whether distinct antidepressants directly 
affect BDNF equally to serotonin remains unknown. Yet, not all patients respond to the 
available drugs, and recent studies challenge the ‘monoamine/neurotrophin hypothesis’ by 
suggesting a more direct change in cellular plasticity such as spine density, the ceramide 
system or AMPA receptors as target for antidepressants (Gulbins et al., 2013). 
Investigating hippocampal tissue of depressed patients thus translating animal studies into 
human reveals that the number of putative stem cells is reduced but neither proliferation 
nor net neurogenesis is affected. Vice versa, antidepressant treatment with the classical 
drugs does not result in increased or normalized cell proliferation suggesting a 
neurogenesis-independent mechanism (David et al., 2009, Lucassen et al., 2010). A new 
therapeutic approach is the treatment with tianeptine, a modified TCA that functions 
independently from the serotonin system. Chronic treatment overcomes the stress-induced 
reduction of precursor cell proliferation in tree shrews while pharmacological properties 
suggest its action through the glutamatergic system with alterations in BDNF release 
(Czeh et al., 2001, McEwen et al., 2010).  
 
Serotonin function in the adult hippocampus  
Cell genesis in the adult hippocampus plays a key role in learning and memory, is 
modulated by serotonin, and involved in antidepressant action. Increased neurogenesis 
leads to more efficiency in pattern separation (Sahay et al., 2011). The advantage of 
continues generation of neurons lies in the immediate or long-term adaption to neurogenic 
stimuli (Kempermann et al., 1997, van Praag et al., 1999), injury, or pathology (Parent et 
al., 1997, Duman et al., 2001). This also includes the response to exogenous stimuli like 
physical exercise that could lead to the development of alternative approaches in 
treatment of neurodegenerative disorders. Running has long been known to provoke 
increased cell proliferation in the hippocampal niche (van Praag et al., 1999, Kronenberg 
et al., 2003). Taking advantage of the genetic loss-of-function model Tph2-/-, we measured 
cell proliferation and differentiation in the adult DG following short-term voluntary wheel 
running (Klempin et al., 2013), and we established that serotonin is necessary for a fast 
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neurogenic response of the niche to changes in physical activity. This new evidence for a 
mechanism of serotonin in brain function elucidates one of its broad modes of action in the 
adult. This knowledge may lead to develop specific pathways that mediate exercise-
dependent cell genesis in the hippocampus that will also have therapeutic relevance. 
Other studies support these findings showing that exercise-plus-antidepressant challenges 
with commonly used drugs in depression, e.g. citalopram or the NE-selective 
antidepressant reboxetine significantly increase BDNF levels in hippocampal regions 
(Russo-Neustadt et al., 1999, Russo-Neustadt et al., 2004). Yet, consequence of chronic 
loss of serotonin pathways in hippocampal function seems not tied to homeostatic 
mechanisms such as compensation by other neurotransmitter systems but more likely to 
an organism response to environmental changes (Klempin et al., 2013). The long-term 
goal is to identify the pathways of serotonin action to facilitate the design of alternative 
approaches for the treatment of depression or age-related decline in learning and memory.  
 
Concluding remarks 
In this chapter we have considered the critical role of serotonin and its receptors in the 
regulation of adult hippocampal neurogenesis (Table 1). Given the potentially central role 
of neurogenesis in cognition and emotional state, it is necessary that research continues to 
open our understanding of the molecular and pharmacological network by which serotonin 
regulates the hippocampal niche. Serotonin’s importance in the modulation of adult 
neurogenesis was first proposed 15 years ago. Since then a growing number of 
pharmacological experiments confirmed its positive impact on cell proliferation and survival 
of newborn neurons. However, here we have identified apparent contradictions and 
divergent hypotheses in the literature, particularly in chronic models of serotonin 
manipulation. The vast number of receptor subtypes and the complex distribution of the 
serotonin system in the brain is likely a major reason for discordance that will be resolved 
in future research. Analyses of the genetically modified mouse models that are depleted in 
brain serotonin from early development throughout adulthood exhibit unexpected 
phenotypes in comparison to predictions derived from the interpretation of 
pharmacological studies; in particular sustained baseline levels. The effects observed in 
these models support the important role of serotonin in adult neurogenesis, but cannot 
discriminate between phenotypes induced by serotonin per se and compensatory 
processes provoked by its life-long depletion. In turn, pharmacological studies show that 
acute and chronic modulations of serotonin in the adult lead to significant neurogenic 
modification but do not reveal the target or the compensatory changes in targets over time.   
We conclude that future work should be focusing on the sources of serotonin and 
the physiologic mechanisms whereby it is released onto hippocampal targets. While 
pharmacological and genetic studies are beginning to define the location and role of 
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specific 5-HT receptor subtypes in hippocampal cell genesis, data regarding the 
downstream regulatory networks is notably slim. A better understanding of paracrine and 
autocrine factors that are serotonin-dependent is necessary for the future development of 
a model of serotonergic/neurogenic mechanisms. Newly generated mouse models that 
can be targeted by optogenetic activation, or silencing of serotonergic fibers that project 
into the hippocampus are important next steps to elucidate serotonin signaling in the 
neurogenic niche. At last, a working model that accounts for the temporal and spatial role 
of serotonin and its receptor targets within the hippocampal niche will likely lead to better 
therapeutic designs for the treatment of cognitive, memory and mood disorders.  
 
Table 1 Summary of recent findings on serotonin influence and modulation of adult hippocampal 
neurogenesis.  
 
Pharmacological serotonin depletion studies  
Brezun & Daszuta 2000 
 
5,7-DHT treatment Raphe lesions lead to decreased 5-HT fiber density in the 
DG associated with decreased number of neurons in 
GCL and SVZ  
Brezun & Daszuta 2000 Raphe 
Transplantation 
Raphe grafts restore serotonergic control on precursor 
cell proliferation and reverse lesion-induced decrease 
Huang & Herbert 2005 PCPA treatment 
5,7-DHT treatment 
No effect on cell proliferation either 14 days (PCPA) or 3 
weeks (5,7-DHT) after  
Jha et al., 2006 PCPA treatment 
5,7-DHT treatment 
Decreases precursor cell proliferation and survival  
Selectively decreases hippocampal 5-HT levels 
Diaz et al., 2013 PCPA treatment Increases survival or newly generated neurons  
Pharmacological receptor targeting studies 
Yan et al., 1997 5-HT1A Mediates the effect of serotonin depletion on decreased 
spine density of granule cells  
Radley & Jacobs 2002 5-HT1A 
postsynaptic 
Ant/agonist treatment affects number of BrdU-positive 
cells / modulates anxiety-related behavior 
Banasr et al., 2004 5-HT1A, 5-HT1B, 
and 5-HT2C 
Ant/agonist treatment reveals differential effects on SVZ 
and SGL newborn cells 
Huang & Herbert 2005 5-HT1A 
postsynaptic 
Agonist treatment following PCPA or 5,7-DHT modulates 
cell proliferation by a direct postsynaptic effect  
Klempin et al., 2010 5-HT1A, 5-HT2  Ant/agonist treatment differentially affects neurogenesis  
Mogha et al., 2012 5-HT1A 5-HT1A receptor signaling is important for normal 
synaptogenesis in the neonatal hippocampus 
Mendez-David et al., 2014 5-HT4 Facilitates maturation of newborn neurons in the DG 
Mouse models with genetically modified serotonin system 
Santarelli et al., 2003 5-HT1A KO mouse 5-HT1A activation stimulates neurogenesis in the DG  
Schmitt et al., 2007 SERT-/- (5-HTT-/-) 
mouse 
Increased synaptic 5-HT levels influence proliferation in 
aged but not young adult and adult mice 
Schipper et al., 2011 SERT-/- rat Increased numbers of DCX-positive cells in the DG 
Migliarini et al., 2012 Tph2::eGFP Increased serotonergic innervation in nucleus accumbens 
and hippocampus 
Diaz et al., 2013 Pet1-/-,  
VMAT2SERT-Cre 
Increased survival or newly generated neurons at 
baseline 
Klempin et al., 2013 Tph2-/- mouse Normal baseline proliferation in serotonin deficient mice 
Sachs et al., 2013 Tph2KI mouse Increased survival or newly generated neurons at 
baseline with increased numbers of DCX-positive cells  
Antidepressant action and neurogenesis  
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Malberg et al., 2000 Flx First shown increase in neurogenesis after prolonged 
treatment with Flx  
Chen et al., 2001 cAMP cAMP signal transduction cascade contributes to 
increased neurogenesis as antidepressant response  
Czeh et al., 2001 Tianeptine Treatment reduces proliferation of precursor cells in the 
DG  
Santarelli et al., 2003 5-HT1A KO 
Flx 
5-HT1A receptors are required for Flx-induced 
hippocampal neurogenesis  
Encinas et al., 2006 Flx Flx acts solely on type-2a progenitors by increasing the 
rate of symmetric cell divisions 
Wang et al., 2008 Flx Chronic treatment accelerates maturation and 
synaptogenesis of immature granule cells  
Benmansour et al., 2008 SSRI Acute BDNF injection into the hippocampus increases 
SERT function 
Soumier et al., 2009 5-HT2C Increases proliferation and mediates the antidepressant 
effect of agomelatine  
Klempin et al., 2010 5-HT1A, 5-HT2C  Latency of Flx action due to additive effects of 5HT1A, 2C 
receptors 
Kobayashi et al., 2010 5-HT4 KO 
Flx 
Flx treatment reverses neuronal maturation (Calbindin 
expression) with up-regulated 5-HT4 signaling  
Diaz et al., 2012 5-HT2B Pharmacological receptor stimulation mimics SSRI-like 
response  
Boldrini et al., 2012  SSRI, TCA Stimulation of angiogenesis and neurogenesis  
Ferres-Coy et al., 2013  RNAi – SERT Acute SERT silencing increases 5-HT release and 
neurogenesis and decreases latency in antidepressant 
action 
Vaidya, Marek et al. 1997  
 
BDNF Decreased BDNF mRNA levels in the DG after 5-HT2A 
and 2C chronic agonist treatment  
Deltheil et al., 2008 BDNF BDNF potentiates the effect of SSRI treatment (in vivo 
intracerebral microdialysis)  
Quesseveur et al., 2013 
 
BDNF  SSRI treatment increases BDNF levels released from 
astrocytes that promote neurogenesis 
Functional role of serotonin in adult neurogenesis 
Russo-Neustadt et al., 2004 SSRI, BDNF, 
exercise 
Exercise-plus-antidepressant challenge led to increased 
BDNF levels in the hippocampus 
Klempin et al., 2013 Tph2-/- mouse No running-induced effect on proliferation when serotonin 
is absent 
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Glossary: 
 
5-HT: 5-hydroxytryptamine, serotonin 
 
5,7-DHT: 5,7-dihydroxytryptamine, a neurotoxin that selectively is taken up by SERT and causes 
neuronal damage upon MAO-A-mediated oxidation. 
8-OH DPAT: 8-hydroxy-2-(dipropylamino)tetralin hydrobromide, standard selective 5-HT1A agonist 
BDNF: brain-derived neurotrophic factor 
 
BrdU: bromodeoxyuridine, a thymidine analog that gets incorporated into the replicating DNA 
(during the S-phase of the cell-cycle) and is commonly used for the detection of proliferating cells.  
 
cAMP: cyclic AMP or 3'-5'-cyclic adenosine monophosphate 
 
DCX: doublecortin, microtubule associated protein and transient marker of immature neurons in the 
DG 
 
DG: dentate gyrus 
 
Flx: fluoxetine, SSRI that is widely used as antidepressant (trade name Prozac) 
 
LTP: long-term potentiation	  
 
PCPA: para-chlorophenylalanine, TPH inhibitor 
 
Pet1: ETS (E-twenty six) transcription factor, expressed predominantly in serotonergic neurons  	  
SERT (Slc6a4, 5-HTT): serotonin transporter, expressed predominantly in serotonergic neurons  
 
SGZ: subgranular zone  
 
SSRI: selective serotonin reuptake inhibitor, treatment increases extracellular serotonin availability 
immediately  
 
Sox2: SRY-related HMG-box gene 2, transcription factor that drives the cell fate of precursor cells 
toward an astrocyte lineage, in the DG it is mainly expressed in stem and type-2a progenitor cells 
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SVZ: subventricular zone  
 
TCA: tricyclic antidepressant	  
 
TPH2: tryptophan hydroxylase 2, rate-limiting enzyme of serotonin synthesis in the brain, 
expression exclusively in serotonergic neurons 
 
VMAT2: vesicular monoamine transporter 2, responsible for packing serotonin into synaptic 
vesicles, expression in serotonergic, but also dopaminergic and noradrenergic neurons  
 
Mouse models: 
VMAT2SERT-CRE: mouse with conditional deletion of VMAT2 in serotonergic neurons that had been 
crossed by VMAT2flox/flox and SERT-Cre mouse lines (expressing Cre recombinase under the control 
of the SERT promoter); uniform reduction of serotonin in all brain regions (more than 95%) 
 
Tph2-/-: Tph2-deficient mouse with constitutive ablation of TPH2 enzyme that leads to serotonin 
depletion in the brain (more than 95% reduction) 
 
Pet1-/-: hypo-serotonergic mouse model in which the majority (80%) of serotonergic neurons in the 
raphe fail to differentiate (85% serotonin reduction) 
 
Tph2KI: Tph2 R439H knock in, hypo-serotonergic mouse bearing a single-nucleotide mutation, 
equivalent to a rare human variant (R441H) identified in depressed patients (80% serotonin 
reduction). 
 
5-HTT-/-: Sert-deficient mouse with 60-80% reduction in brain serotonin level, but about 10-fold 
increase in extracellular serotonin concentrations 
 
Tph2::eGFP: Tph2-deficient mouse model that carries an additional eGFP cDNA knocked in into the 
Tph2 locus and allows the visualization of serotonergic fibers in Tph2+/- and Tph2-/- mice. 
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  B 
Pharmacological 
manipulation 
Drug effect type-1 type-2a/2b type-3 net neurogenesis BDNF 
5,7-DHT Lesion of 5-HT neurons n/a – – / 0 – / 0 
PCPA Inhibition of 5-HT synthesis – – –  – / + 
5-HT1A 
(postsynaptic) 
Stimulation 
Blockage 
n/a 
– 
++ 
– 
+ 
– 
+ 
– 
5-HT1B Stimulation n/a + n/a n/a 
5-HT2A Stimulation Blockage n/a 
– 
+ 
n/a 
0 
               – 
               0 
↓ 
 
5-HT2B Stimulation Blockage 
Induces antidepressant-like response 
Decreases 5-HT levels  
5-HT2C Stimulation Blockage 
– 
n/a 
– / 0 
+ 
+ 
0 
                ++ 
                0 
↓ 
↑ 
5-HT4 Stimulation n/a n/a + + 
SSRI-Flx1 Increases extra-cellular 5-HT levels No effect ++ +                 ++ 
↑ 
Animal models Phenotype     
5-HT1A KO  0 0 n/a n/a 
Tph2-/- No serotonin 0 Increased Sox2 0                 0 ↑ 
VMAT2SERT-Cre Reduced 5-HT levels 0 0 0 ++ 
Tph2KI Reduced 5-HT levels n/a 0 +                 ++ ↑ 
Pet1-/- Reduced 5-HT levels n/a 0 n/a ++ 
SERT-/- Increased extra-cellular 5-HT levels  n/a + + n/a 
1 refer for summary to Klempin et al. 2010  
 
Figure 1 
Illustration of serotonin’s (5-HT) mode of action in the course of adult hippocampal 
neurogenesis.  
A. Serotonergic neurons are located in the brainstem raphe nuclei where 5-HT is synthesized by 
TPH2, packaged into vesicles and transported by VMAT2, while its re-uptake into the presynaptic 
neurons is ensued by its selective transporter (SERT) (the embedded square marks a synapse). 
SERT and presynaptic 5-HT1A autoreceptors on serotonergic neurons are targets for SSRIs, which 
may also modulate BDNF levels. Dense tracts of serotonergic fibers terminate in the hippocampus 
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with one projecting into the molecular layer (ML) and another to the hilus, where it synapses on 
principle neurons and interneurons (in orange). Hilar interneurons in the dentate gyrus (DG) in turn 
contact immature and newly generated granule cells suggesting an indirect effect of serotonin 
action. In the DG, type-1, type-2a/b, type-3, immature and mature neurons mark the six 
developmental steps within adult neurogenesis. Type-2a cells are highly proliferative. The variety of 
5-HT receptors in the DG is differentially expressed with 5-HT1A receptor immunolabeling found on 
type-1 to type-2b cells in the subgranular zone (SGZ), and hilar interneurons. 5-HT2B and 2C 
receptors mostly mark adult granule cells whereas 5-HT2A receptor labeling reveals a dense 
staining in the hilus; 5-HT3 receptor expression was seen on hilar interneurons. BDNF, brain-
derived neurotrophic factor; GCL, granule cell layer; SSRI, selective serotonin re-uptake inhibitor; 
TPH2, tryptophan hydroxylase 2; VMAT2, vesicular monoamine transporter 2. B. The table 
summarizes the effect of pharmacological targeting and genetic manipulation of the serotonin 
system on the generation of newborn neurons. Animal models developmentally manipulated in 
brain serotonin do not show a drastic change in adult neurogenesis but reveal long-term effects on 
the survival of newborn neurons and neurotrophin signaling (BDNF). Characters: +/++ or – refer to 
increased cell numbers/positive effects or decreased cell numbers/negative effects; 0 no change; 
n/a not analyzed; ↑↓ increased or decreased BDNF levels in the hippocampus 
 
